Clinical and laboratory findings in patients with leukocyte adhesion deficiency type I: A multicenter study in Turkey.


Journal

Clinical and experimental immunology
ISSN: 1365-2249
Titre abrégé: Clin Exp Immunol
Pays: England
ID NLM: 0057202

Informations de publication

Date de publication:
10 2021
Historique:
revised: 16 07 2021
received: 23 05 2021
accepted: 18 07 2021
pubmed: 27 7 2021
medline: 24 12 2021
entrez: 26 7 2021
Statut: ppublish

Résumé

Leukocyte adhesion deficiency type I is a rare primary immunodeficiency disorder characterized by mutations in the ITGB2 gene encoding CD18. We present clinical and immunological features of 15 patients with leukocyte adhesion deficiency type 1 (LAD-1). Targeted next-generation sequencing was performed with either a primary immunodeficiency gene panel comprising 266 genes or a small LAD-panel consisting of five genes for genetic analysis. To measure the expression level of integrins on the leukocyte surface, flow cytometry analysis was performed. The median age of the patients at diagnosis was 3 (1-48) months. Eleven (73%) of the 15 patients had a LAD-1 diagnosis in their first 6 months and 14 (93%) patients had consanguineous parents. Delayed separation of the umbilical cord was present in 80% (n = 12) of the patients in our cohort, whereas omphalitis was observed in 53% (n = 8) of the patients. Leukocytosis with neutrophil predominance was observed in 73% (n = 11) patients. Nine distinct variants in the ITGB2 gene in 13 of the 15 patients with LAD-1 were characterized, two of which (c.305_306delAA and c.779_786dup) are novel homozygous mutations of ITGB2. Four unrelated patients from Syria had a novel c.305_306delAA mutation that might be a founder effect for patients of Syrian origin. Four (27%) patients underwent hematopoietic stem cell transplantation. Two patients died because of HSCT complications and the other two are alive and well. Early differential diagnosis of the patients is critical in the management of the disease and genetic evaluation provides a basis for family studies and genetic counseling.

Identifiants

pubmed: 34310689
doi: 10.1111/cei.13645
pmc: PMC8446394
doi:

Substances chimiques

CD18 Antigens 0

Types de publication

Clinical Trial Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

47-55

Subventions

Organisme : Türkiye Bilimsel ve Teknolojik Araştirma Kurumu
ID : 315S125

Informations de copyright

© 2021 British Society for Immunology.

Références

J Biol Chem. 1992 Mar 15;267(8):5482-7
pubmed: 1347532
J Clin Immunol. 2019 Apr;39(3):309-315
pubmed: 30919141
J Clin Immunol. 2016 Oct;36(7):627-30
pubmed: 27492259
Ann N Y Acad Sci. 2012 Feb;1250:50-5
pubmed: 22276660
Periodontol 2000. 2015 Oct;69(1):142-59
pubmed: 26252407
Front Immunol. 2020 Dec 16;11:612703
pubmed: 33391282
J Clin Immunol. 2010 Sep;30(5):756-60
pubmed: 20549317
Curr Opin Hematol. 2013 Jan;20(1):16-25
pubmed: 23207660
J Infect Dis. 1985 Oct;152(4):668-89
pubmed: 3900232
J Pediatr Hematol Oncol. 2019 Jan;41(1):e3-e6
pubmed: 29750748
Mol Immunol. 2013 Aug;55(1):49-58
pubmed: 23253941
J Clin Immunol. 2020 Jan;40(1):24-64
pubmed: 31953710
J Allergy Clin Immunol Pract. 2018 Jul - Aug;6(4):1418-1420.e10
pubmed: 29371071
Fertil Steril. 2006 Feb;85(2):494.e15-8
pubmed: 16595236
Blood Cells Mol Dis. 2012 Jan 15;48(1):53-61
pubmed: 22134107
J Allergy Clin Immunol. 2009 Dec;124(6):1356-8
pubmed: 19864007
Clin Exp Immunol. 2021 Oct;206(1):47-55
pubmed: 34310689
J Fungi (Basel). 2017 Sep 27;3(4):
pubmed: 29371568
Biochem Biophys Res Commun. 1992 May 15;184(3):1460-7
pubmed: 1590804
Clin Immunol. 2018 Jun;191:75-80
pubmed: 29548898
Eur J Clin Invest. 2019 Feb;49(2):e13047
pubmed: 30412664
J Clin Immunol. 2007 May;27(3):302-7
pubmed: 17294145
Sci Transl Med. 2014 Mar 26;6(229):229ra40
pubmed: 24670684
Exp Hematol. 2002 Mar;30(3):252-61
pubmed: 11882363
Biochem Biophys Res Commun. 2011 Jan 28;404(4):1099-104
pubmed: 21195692
J Clin Invest. 1999 Jan;103(1):97-106
pubmed: 9884339

Auteurs

Ismail Yaz (I)

Division of Pediatric Immunology, Department of Pediatrics, Hacettepe University Medical School, Ankara, Turkey.

Begum Ozbek (B)

Division of Pediatric Immunology, Department of Pediatrics, Hacettepe University Medical School, Ankara, Turkey.

Hacer Neslihan Bildik (HN)

Division of Pediatric Immunology, Department of Pediatrics, Hacettepe University Medical School, Ankara, Turkey.

Cagman Tan (C)

Division of Pediatric Immunology, Department of Pediatrics, Hacettepe University Medical School, Ankara, Turkey.

Sevil Oskay Halacli (S)

Division of Pediatric Immunology, Department of Pediatrics, Hacettepe University Medical School, Ankara, Turkey.

Elif Soyak Aytekin (E)

Division of Pediatric Immunology, Department of Pediatrics, Hacettepe University Medical School, Ankara, Turkey.

Saliha Esenboga (S)

Division of Pediatric Immunology, Department of Pediatrics, Hacettepe University Medical School, Ankara, Turkey.

Sukru Cekic (S)

Department of Pediatrics, Uludag University Medical School, Bursa, Turkey.

Sara Sebnem Kilic (SS)

Department of Pediatrics, Uludag University Medical School, Bursa, Turkey.

Ozlem Keskin (O)

Department of Pediatric Immunology and Allergy, Gaziantep University Medical School, Gaziantep, Turkey.

Karin van Leeuwen (K)

Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.

Dirk Roos (D)

Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.

Deniz Cagdas (D)

Division of Pediatric Immunology, Department of Pediatrics, Hacettepe University Medical School, Ankara, Turkey.

Ilhan Tezcan (I)

Division of Pediatric Immunology, Department of Pediatrics, Hacettepe University Medical School, Ankara, Turkey.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH